Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials - PubMed (original) (raw)
Review
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S Aday et al. Psychopharmacology (Berl). 2022 Jun.
Abstract
Rationale: Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and effective condition masking have been raised as critical limitations to the interpretability of the research.
Objective: In this article, we review the many methodological challenges of conducting psychedelic clinical trials and provide recommendations for improving the rigor of future research.
Results: Although some challenges are shared with psychotherapy and pharmacology trials more broadly, psychedelic clinical trials have to contend with several unique sources of potential bias. The subjective effects of a high-dose psychedelic are often so pronounced that it is difficult to mask participants to their treatment condition; the significant hype from positive media coverage on the clinical potential of psychedelics influences participants' expectations for treatment benefit; and participant unmasking and treatment expectations can interact in such a way that makes psychedelic therapy highly susceptible to large placebo and nocebo effects. Specific recommendations to increase the success of masking procedures and reduce the influence of participant expectancies are discussed in the context of study development, participant recruitment and selection, incomplete disclosure of the study design, choice of active placebo condition, as well as the measurement of participant expectations and masking efficacy.
Conclusion: Incorporating the recommended design elements is intended to reduce the risk of bias in psychedelic clinical trials and thereby increases the ability to discern treatment-specific effects of psychedelic therapy.
Keywords: Clinical trials; Expectancies; Masking; Placebo effect; Psychedelic therapy; Psychedelics; Recommendations; Treatment expectations.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Conflict of interest JDW was a paid consultant for Silo Pharma and Filament Health last in June 2021. BDH is a paid consultant for Clairvoyant Therapeutics. None of the other co-authors have any conflicts of interest to declare.
Figures
Fig. 1
Treatment-nonspecific effects in clinical trials. (a) Hypothetical results of a clinical trial to delineate the sources of treatment-specific and treatment-nonspecific effects. Including placebo and no treatment control conditions allows trialists to identify treatment-specific effects (figure inspired by Wampold et al. 2016). (b) In a clear illustration of expectancy effects, Bingel et al. (2011) measured participants’ pain intensities before (i.e., Baseline) and after receiving remifentanil while manipulating participant expectancies across three groups (e.g., No expectancy, Positive expectancy, or Negative expectancy). They found that priming positive treatment expectancy doubled the analgesic effect of remifentanil when compared to no expectancy. In contrast, inducing negative treatment expectancies eliminated the analgesic effect. (c) Gold et al. (2017) demonstrated that treatment effect sizes vary as a function of the type control group utilized
Fig. 2
Stages of psychedelic therapy. Psychedelic therapy typically involves preparation, dosing, and integration sessions
Fig. 3
Recommendations for improving methodology in psychedelic trials. Overview of our recommendations for improving experimental methodology in future clinical trials with psychedelics
Similar articles
- Psychedelics and Psychotherapy.
Nayak S, Johnson MW. Nayak S, et al. Pharmacopsychiatry. 2021 Jul;54(4):167-175. doi: 10.1055/a-1312-7297. Epub 2020 Dec 7. Pharmacopsychiatry. 2021. PMID: 33285578 Review. - Expectancy Effects in Psychedelic Trials.
Szigeti B, Heifets BD. Szigeti B, et al. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May;9(5):512-521. doi: 10.1016/j.bpsc.2024.02.004. Epub 2024 Feb 20. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024. PMID: 38387698 Review. - Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler M, Jelen L, Rucker J. Butler M, et al. Psychopharmacology (Berl). 2022 Oct;239(10):3047-3055. doi: 10.1007/s00213-022-06221-6. Epub 2022 Sep 5. Psychopharmacology (Berl). 2022. PMID: 36063208 Free PMC article. - Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders [Internet].
Chao YS, Horton J. Chao YS, et al. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Jun. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Jun. PMID: 36170470 Free Books & Documents. Review. - Blinding and expectancy confounds in psychedelic randomized controlled trials.
Muthukumaraswamy SD, Forsyth A, Lumley T. Muthukumaraswamy SD, et al. Expert Rev Clin Pharmacol. 2021 Sep;14(9):1133-1152. doi: 10.1080/17512433.2021.1933434. Epub 2021 Aug 26. Expert Rev Clin Pharmacol. 2021. PMID: 34038314
Cited by
- History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers.
Barber M, Gardner J, Carter A. Barber M, et al. J Bioeth Inq. 2024 Oct 4. doi: 10.1007/s11673-024-10386-4. Online ahead of print. J Bioeth Inq. 2024. PMID: 39365395 - Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats.
Fisher EL, Smith R, Conn K, Corcoran AW, Milton LK, Hohwy J, Foldi CJ. Fisher EL, et al. Transl Psychiatry. 2024 Sep 30;14(1):394. doi: 10.1038/s41398-024-03103-7. Transl Psychiatry. 2024. PMID: 39349428 Free PMC article. - Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.
Nicholas CR, Banks MI, Lennertz RC, Wenthur CJ, Krause BM, Riedner BA, Smith RF, Hutson PR, Sauder CJ, Dunne JD, Roseman L, Raison CL. Nicholas CR, et al. Transl Psychiatry. 2024 Sep 12;14(1):372. doi: 10.1038/s41398-024-03059-8. Transl Psychiatry. 2024. PMID: 39266503 Free PMC article. - Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C. Schipper S, et al. Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2. Cochrane Database Syst Rev. 2024. PMID: 39260823 - Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F, Idrees Chaudhary N, van der Meer PB, Batalla A. Gomez-Escolar A, et al. CNS Drugs. 2024 Oct;38(10):771-789. doi: 10.1007/s40263-024-01101-3. Epub 2024 Jul 20. CNS Drugs. 2024. PMID: 39033264 Review.
References
- Aday JS (2021) Delineating the association between psychedelic drug use and facets of gratitude, aesthetic experience, and relationships with nature. Dissertation, Central Michigan University
- Aday JS, Bloesch EK, Davoli CC (2020a) 2019: A year of expansion in psychedelic research, industry, and deregulation. Drug Sci Pol Law 6. 10.1177/2050324520974484 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources